SUPPREMOL LAUNCHED AS A NEW COMPANY FINANCED BY Z-CUBE
Landmark contract signed in Munich.
Milan (Italy) and Munich (Germany) 28th November 2005 – Z-Cube, the corporate venture capital arm of the Zambon Group took another important step forwards in fostering pharmaceutical innovation, signing a contract to provide finance and expert support to SuppreMol GmbH. This marked the project's official launch as a new company after several years of basic research and proof of principle of a new therapeutic approach in autoimmune diseases. SuppreMol is a spin-off company of the Max-Planck-Institute of Biochemistry in Munich, Germany set up with the support of Garching Innovation GmbH, the technology transfer office of the Max Planck Society.
"Suppremol is an important asset in our portfolio, with immense potential thanks to its strong team and novel therapeutic approach", explained Claudio Semeraro, Executive Director of Z-Cube Srl. "Moreover, it is a noteworthy example of how successfully our research/industry partnership model is working in Europe as well as the United States".
Peter Buckel, Chief Executive Officer of SuppreMol GmbH added:"We are very pleased to be a member of the Z-Cube family. This partnership not only provides us with funding but also brings significant strategic and enterprise support which benefits from the expertise of an important pharmaceutical player in our target disease area. To our knowledge this is the first financing of a Biotech start-up in Germany this year".
Ulrich Mahr, senior start-up manager of Garching Innovation GmbH stated: "The combination of excellent research results from the Max-Planck Institute of Biochemistry with the strong pharmaceutical background of Z-Cube form a very fruitful basis for the future success of our new portfolio company SuppreMol".
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
